Vanguard Asset Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.4M Buy
48,922
+2,745
+6% +$723K 0.01% 588
2026
Q2
$10.5M Buy
46,177
+1,207
+3% +$215K 0.01% 710
2026
Q1
$7.76M Buy
+44,970
New +$8.34M 0.01% 735

Other funds holding CRL

Vanguard Asset Management's CRL Position: Q3 2026 in Review

Vanguard Asset Management increased its Charles River Laboratories (CRL) stake by 5.9% in Q3 2026, buying an estimated $723K and bringing the position to 48,922 shares worth $14.4M. The position accounts for 0.01% of the portfolio, ranked #588.

Vanguard Asset Management first reported a position in CRL in Q1 2026 and has held it in 3 quarters since. 642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Vanguard Asset Management held 48,922 shares of Charles River Laboratories worth $14.4M as of Q3 2026.
  • Vanguard Asset Management bought 2,745 Charles River Laboratories shares in Q3 2026, an estimated $723K.
  • Charles River Laboratories made up 0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #588 holding.
  • Vanguard Asset Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 3 quarters since.
  • 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.